Format

Send to

Choose Destination
J Hematol Oncol. 2017 Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2.

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Author information

1
Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, 1 Avenue Claude Vellefaux, 75475, Paris, France. pierre.fenaux@aphp.fr.
2
Marien Hospital Düsseldorf, Düsseldorf, Germany.
3
AZ St-Jan BruggeAV, Brugge, Belgium.
4
Purpan Pavillion de Medecines, Centre Hospitalier Universitaire, Toulouse, France.
5
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
6
Radboud University Medical Centre, Nijmegen, The Netherlands.
7
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
8
Karolinska University Hospital, Stockholm, Sweden.
9
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA.
10
CHU Brabois, University Center of Medicine, Vandoeuvre, France.
11
Cleveland Clinic, Cleveland, OH, USA.
12
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
13
Hospital Universitario de Salamanca, Salamanca, Spain.
14
Stanford Cancer Institute, Stanford, CA, USA.
15
Rush University Medical Center, Chicago, IL, USA.
16
Celgene Corporation, Summit, NJ, USA.
17
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Abstract

BACKGROUND:

Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed.

METHODS:

We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials.

RESULTS:

A total of 33.9, 34.3, and 31.8% patients were aged <65 years, ≥65 to <75 years, and ≥75 years, respectively. Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p = 0.022 vs. ≥65 to <75 years; p = 0.047 vs. ≥75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray's test, p = 0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence ≥26 weeks.

CONCLUSIONS:

Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00065156 and NCT00179621.

KEYWORDS:

Acute myeloid leukemia; Age; Lenalidomide; Myelodysplastic syndromes; del(5q)

PMID:
28651604
PMCID:
PMC5485496
DOI:
10.1186/s13045-017-0491-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center